CD8A and neoplasm: In 2016, in fact, Deguchi et al. found that Eritoran inhibited lung cancer progression in vivo, likely due to reduced tumor angiogenesis, lower levels of TAMs and CD11b+Ly6C++Ly6G– myeloid-derived cells infiltration with a consequent increase in CD8+ T-cell tumor infiltration [148].